CHEK2 and breast cancer: Therefore, while it is now technically feasible to design a massively parallel sequencing-based test that can accurately and relatively inexpensively identify mutations in a panel of breast cancer susceptibility genes that includes ATM and CHEK2 [72], it may be inappropriate to introduce such a test into widespread use before a clinically validated method of assessing unclassified missense substitutions in these genes has been developed.